Michiaki Kohno

List of Publications by Year
in descending order

41 papers	3,096 citations	185998 28 h-index	276539 41 g-index
43 all docs	43 docs citations	43 times ranked	4160 citing authors

#	Article	IF	Citations
1	Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 1999, 18, 813-822.	2.6	625
2	Targeting the ERK signaling pathway in cancer therapy. Annals of Medicine, 2006, 38, 200-211.	1.5	357
3	Specific Activation of the p38 Mitogen-activated Protein Kinase Signaling Pathway and Induction of Neurite Outgrowth in PC12 Cells by Bone Morphogenetic Protein-2. Journal of Biological Chemistry, 1999, 274, 26503-26510.	1.6	193
4	Extracellular Signalâ€“Regulated Kinase Inhibition Slows Disease Progression in Mice with Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 1604-1614.	3.0	133
5	Blockade of the Extracellular Signal-regulated Kinase Pathway Induces Marked G1 Cell Cycle Arrest and Apoptosis in Tumor Cells in Which the Pathway Is Constitutively Activated. Journal of Biological Chemistry, 2001, 276, 2686-2692.	1.6	119
6	Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E643-E651.	1.8	115
7	ERK Pathway Positively Regulates the Expression of Sprouty Genes. Biochemical and Biophysical Research Communications, 2001, 285, 1084-1088.	1.0	101
8	Activation of the 41/43â€‰kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene, 1998, 17, 57-65.	2.6	95
9	Characterization of the Bone Morphogenetic Protein-2 as a Neurotrophic Factor. Journal of Biological Chemistry, 1996, 271, 17360-17365.	1.6	92
10	GEF-H1 Mediates Tumor Necrosis Factor-Î±-induced Rho Activation and Myosin Phosphorylation. Journal of Biological Chemistry, 2009, 284, 11454-11466.	1.6	84
11	Distribution and Characterization of Specific Cellular Binding Proteins for Bone Morphogenetic Protein-2. Journal of Biological Chemistry, 1995, 270, 5476-5482.	1.6	83
12	Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochemical and Biophysical Research Communications, 2003, 304, 801-806.	1.0	80
13	Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with crossâ€resistance to a wide range of DNAâ€damaging drugs. Cancer Science, 2008, 99, 376-384.	1.7	79
14	ERK1/2 phosphorylate GEF-H1 to enhance its guanine nucleotide exchange activity toward RhoA. Biochemical and Biophysical Research Communications, 2008, 368, 162-167.	1.0	65
15	Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity. Biochemical and Biophysical Research Communications, 2005, 330, 1306-1313.	1.0	61
16	Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Progress in Cell Cycle Research, 2003, 5, 219-24.	0.9	58
17	Prolonged Nuclear Retention of Activated Extracellular Signal-regulated Kinase 1/2 Is Required for Hepatocyte Growth Factor-induced Cell Motility. Journal of Biological Chemistry, 2002, 277, 28256-28264.	1.6	56
18	Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. Journal of Cell Science, 2005, 118, 5861-5871.	1.2	54

#	Article	IF	Citations
19	Targeting the Extracellular Signal-Regulated Kinase Pathway in Cancer Therapy. Biological and Pharmaceutical Bulletin, 2011, 34, 1781-1784.	0.6	54
20	Synthesis and structureâ€“activity relationships of thioflavone derivatives as specific inhibitors of the ERK-MAP kinase signaling pathway. Bioorganic and Medicinal Chemistry, 2004, 12, 2397-2407.	1.4	46
21	Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model. Nephrology Dialysis Transplantation, 2012, 27, 1351-1358.	0.4	46
22	Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochemical and Biophysical Research Communications, 2006, 339, 1171-1177.	1.0	44
23	Blockade of the ERK or PI3Kâ€“Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochemical and Biophysical Research Communications, 2010, 391, 1610-1615.	1.0	42
24	Cell Type-specific Modulation of Cell Growth by Transforming Growth Factor Î²1 Does Not Correlate with Mitogen-activated Protein Kinase Activation. Journal of Biological Chemistry, 1995, 270, 30686-30692.	1.6	40
25	Bone Morphogenetic Protein-2 Promotes Survival and Differentiation of Striatal GABAergic Neurons in the Absence of Glial Cell Proliferation. Journal of Neurochemistry, 2002, 72, 2264-2271.	2.1	38
26	Blockade of the phosphatidylinositol-3-kinaseâ€“Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated. Molecular Cancer Therapeutics, 2007, 6, 1133-1142.	1.9	38
27	Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochemical and Biophysical Research Communications, 2006, 340, 560-566.	1.0	36
28	Requirement for ERK MAP kinase in mouse preimplantation development. Development (Cambridge), 2007, 134, 2751-2759.	1.2	33
29	ERK signaling promotes cell motility by inducing the localization of myosin 1E to lamellipodial tips. Journal of Cell Biology, 2016, 214, 475-489.	2.3	29
30	Anticancer Drugs Up-regulate HspBP1 and Thereby Antagonize the Prosurvival Function of Hsp70 in Tumor Cells. Journal of Biological Chemistry, 2007, 282, 35430-35439.	1.6	28
31	SH3P2 is a negative regulator of cell motility whose function is inhibited by ribosomal S6 kinase-mediated phosphorylation. Genes To Cells, 2011, 16, 514-526.	0.5	23
32	Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor. Journal of Biological Chemistry, 2012, 287, 10289-10300.	1.6	22
33	Enantioselective Total Synthesis of (+)â€Ottelione A, (â^')â€Ottelione B, (+)â€3â€epiâ€Ottelione A and Preliminary Evaluation of Their Antitumor Activity. Chemistry - A European Journal, 2007, 13, 9866-9881.	1.7	21
34	Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells. Biochemical and Biophysical Research Communications, 2009, 378, 650-655.	1.0	16
35	ERK Regulates Renal Cell Proliferation and Renal Cyst Expansion in inv Mutant Mice. Acta Histochemica Et Cytochemica, 2009, 42, 39-45.	0.8	16
36	Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models. Clinical Cancer Research, 2010, 16, 1170-1178.	3.2	15

#	Article	IF	Citations
37	Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models. Biochemical and Biophysical Research Communications, 2013, 433, 456-462.	1.0	15
38	Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state. International Journal of Urology, 2005, 12, 899-905.	0.5	14
39	Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Potential effect on immune surveillance. Biochemical and Biophysical Research Communications, 2007, 360, 280-285.	1.0	10
40	Peumusolide A, unprecedented NES non-antagonistic inhibitor for nuclear export of MEK. Tetrahedron Letters, 2010, 51, 1678-1681.	0.7	10
41	KGFR as a possible therapeutic target in middle ear cholesteatoma. Acta Oto-Laryngologica, 2014, 134, 1121-1127.	0.3	10